<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="476">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154955</url>
  </required_header>
  <id_info>
    <org_study_id>210-9451-203</org_study_id>
    <nct_id>NCT05154955</nct_id>
  </id_info>
  <brief_title>A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat</brief_title>
  <official_title>A Multi-Center, Randomized, Double-Blinded, Vehicle-Controlled Study of the Safety and Efficacy of 10XB-101 in Adult Subjects With Submental Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>10xBio, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>10xBio, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine the safety and efficacy of 10XB-101 vs.&#xD;
      vehicle (placebo) for adults with excessive submental fat (SMF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinician Submental Fat Scale (CSFS)</measure>
    <time_frame>24 weeks after final injection treatment</time_frame>
    <description>Change from Baseline after final treatment. CSFS is a 5 point scale, with a higher score indicating higher severity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Submental Fat Scale (PSFS)</measure>
    <time_frame>24 weeks after final injection treatment</time_frame>
    <description>Change from Baseline after final treatment. PSFS is a 5 point scale, with a higher score indicating higher severity</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Submental Fat</condition>
  <arm_group>
    <arm_group_label>10XB-101 Solution for Injection, 2.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 10XB-101 Solution for Injection, 2.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10XB-101 Solution for Injection, 3.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 10XB-101 Solution for Injection, 3.0% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10XB-101 Solution for Injection, 4.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 10XB-101 Solution for Injection, 4.5% via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10XB-101 Vehicle Solution for Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive 10XB-101 Vehicle Solution for Injection, via subcutaneous injection up to 10 mL. Injection treatment will occur once every 4-6 weeks for up to 6 treatments.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10XB-101 Solution for Injection</intervention_name>
    <description>One of the three concentrations of 10XB-101 will be evaluated against placebo for submental fat reduction.</description>
    <arm_group_label>10XB-101 Solution for Injection, 2.0%</arm_group_label>
    <arm_group_label>10XB-101 Solution for Injection, 3.0%</arm_group_label>
    <arm_group_label>10XB-101 Solution for Injection, 4.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>10XB-101 Vehicle Solution for Injection</intervention_name>
    <description>This is the placebo control</description>
    <arm_group_label>10XB-101 Vehicle Solution for Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a male or non-pregnant female 18 to 65 years old.&#xD;
&#xD;
          -  Subject has provided written informed consent.&#xD;
&#xD;
          -  Subject has qualifying Submental Fat evaluation score.&#xD;
&#xD;
          -  Subject has had a stable body weight for the past 6 months prior to starting study.&#xD;
&#xD;
          -  Subject is willing to undergo test article injections as directed, comply with study&#xD;
             instructions, and commit to all follow-up visits for the duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.&#xD;
&#xD;
          -  Subject has loose skin in the submental area, diffuse SMF, or prominent platysmal&#xD;
             bands at rest that may interfere with evaluation of localized fat, in the opinion of&#xD;
             the investigator.&#xD;
&#xD;
          -  Subject has had any prior treatment for SMF (e.g., deoxycholic acid, cryotherapy,&#xD;
             liposuction, surgery).&#xD;
&#xD;
          -  Subject has any medical condition that affects clotting and/or platelet function&#xD;
&#xD;
          -  Subject has a history of allergy or sensitivity to polidocanol or any of the other&#xD;
             ingredients in the test articles.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site 03</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 02</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 01</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

